Stock Track | Arvinas Soars 5.17% in Pre-Market on Positive Quarterly Results and Promising Drug Updates

Stock Track

02-11

Arvinas Holding Company LLC saw its stock surge 5.17% in pre-market trading on Tuesday, outperforming the broader market.

The biopharmaceutical company's impressive gains were driven by its better-than-expected fourth quarter 2024 earnings report and positive updates on its drug pipeline. Arvinas reported a narrower net loss of $0.63 per share, beating analyst estimates of a $0.96 loss. The company also announced that its cash reserves of $1.04 billion as of December 31, 2024 would be sufficient to fund operations until 2027.

Furthermore, Arvinas provided promising updates on its collaboration with Pfizer, including plans to announce topline data for its oral PROTAC degrader vepdegestrant in the near future. The company's strong cash position and promising drug candidates fueled investor optimism, leading to the significant pre-market rally.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1102531516"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1102531516\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1102531516?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-11 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102531516","market":"hk","top_or_hot":-1,"title":"Stock Track | Arvinas Soars 5.17% in Pre-Market on Positive Quarterly Results and Promising Drug Updates","media":"Stock Track","content":"<p>Arvinas Holding Company LLC saw its stock surge 5.17% in pre-market trading on Tuesday, outperforming the broader market.</p>\n\n<p>The biopharmaceutical company's impressive gains were driven by its better-than-expected fourth quarter 2024 earnings report and positive updates on its drug pipeline. Arvinas reported a narrower net loss of $0.63 per share, beating analyst estimates of a $0.96 loss. The company also announced that its cash reserves of $1.04 billion as of December 31, 2024 would be sufficient to fund operations until 2027.</p>\n\n<p>Furthermore, Arvinas provided promising updates on its collaboration with Pfizer, including plans to announce topline data for its oral PROTAC degrader vepdegestrant in the near future. The company's strong cash position and promising drug candidates fueled investor optimism, leading to the significant pre-market rally.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Arvinas Soars 5.17% in Pre-Market on Positive Quarterly Results and Promising Drug Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Arvinas Soars 5.17% in Pre-Market on Positive Quarterly Results and Promising Drug Updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-11 21:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Arvinas Holding Company LLC saw its stock surge 5.17% in pre-market trading on Tuesday, outperforming the broader market.</p>\n\n<p>The biopharmaceutical company's impressive gains were driven by its better-than-expected fourth quarter 2024 earnings report and positive updates on its drug pipeline. Arvinas reported a narrower net loss of $0.63 per share, beating analyst estimates of a $0.96 loss. The company also announced that its cash reserves of $1.04 billion as of December 31, 2024 would be sufficient to fund operations until 2027.</p>\n\n<p>Furthermore, Arvinas provided promising updates on its collaboration with Pfizer, including plans to announce topline data for its oral PROTAC degrader vepdegestrant in the near future. The company's strong cash position and promising drug candidates fueled investor optimism, leading to the significant pre-market rally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARVN","symbol_name":"Arvinas Holding Company LLC","start_time":0,"source_url":"","article_id":"1102531516","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102531516","pubTimestamp":1739279028,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Arvinas Holding Company LLC saw its stock surge 5.17% in pre-market trading on Tuesday, outperforming the broader market.The biopharmaceutical company's impressive gains were driven by its better-than-expected fourth quarter 2024 earnings report and positive updates on its drug pipeline. Arvinas reported a narrower net loss of $0.63 per share, beating analyst estimates of a $0.96 loss. The company also announced that its cash reserves of $1.04 billion as of December 31, 2024 would be sufficient ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARVN":"Arvinas Holding Company LLC"},"translate_title":"股票赛道Arvinas盘前飙升5.17%，因积极的季度业绩和有希望的药物更新","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARVN":1},"content_text":"Arvinas Holding Company LLC saw its stock surge 5.17% in pre-market trading on Tuesday, outperforming the broader market.\nThe biopharmaceutical company's impressive gains were driven by its better-than-expected fourth quarter 2024 earnings report and positive updates on its drug pipeline. Arvinas reported a narrower net loss of $0.63 per share, beating analyst estimates of a $0.96 loss. The company also announced that its cash reserves of $1.04 billion as of December 31, 2024 would be sufficient to fund operations until 2027.\nFurthermore, Arvinas provided promising updates on its collaboration with Pfizer, including plans to announce topline data for its oral PROTAC degrader vepdegestrant in the near future. The company's strong cash position and promising drug candidates fueled investor optimism, leading to the significant pre-market rally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}